SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co.
MTC 2.200-6.4%3:41 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: twt who wrote (593)11/23/1998 6:29:00 PM
From: Anthony Wong  Read Replies (1) of 2539
 
twt, of course Celebrex will not be a threat to Enbrel or vice versa. Celebrex will be a threat to NSAIDs. Centocor's Remicade, if approved as a rheumatoid-arthritis treatment, would be a threat to Enbrel.

MTC should be trading in a narrow trading range until it shoots up on Celebrex approval (or more exact, the advisory panel's recommendation of approval).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News